SEC Filing Summary: Biozone Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Biozone Pharmaceuticals, Inc. on January 17, 2014, reporting events occurring on January 16, 2014. The filing discloses the closing of a private placement offering of equity securities.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance. Key figures include:
- Gross Proceeds: $2,750,000
- Net Proceeds: $2,612,500
- Shares Issued: 5,500,000 shares of common stock
- Warrants Issued: 5,500,000 warrants (10-year term, $0.50 exercise price)
- Investor Count: 8 accredited investors
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the issuance of unregistered securities. The transaction was executed under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). Palladium Capital Advisors, LLC served as the placement agent.
Outlook, Risks, and Commentary
Management commentary is limited to the execution of the offering. The filing notes that the securities were not registered under the Securities Act of 1933. No specific guidance, risk factors, or contingencies regarding future operations are detailed in this specific report, though the full Securities Purchase Agreement and Warrant are filed as exhibits.
Investor Verification Checklist
- Verify the use of the $2,612,500 net proceeds as disclosed in the full Securities Purchase Agreement (Exhibit 10.1).
- Review the terms of the 10-year warrants (Exhibit 10.2) for potential dilution impact.
- Confirm the company's current cash position and runway post-transaction.
- Check for any subsequent filings regarding the registration rights of the new investors.